Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...

AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used with platinum-doublet chemotherapy ...

Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...

Health insurance promises coverage for modern treatments, but the definition is vague. Bevacizumab, used for nearly two ...

Enspyre is a next generation sequencing (NGS) preparation technology enabling higher sensitivity variant calling from a fraction of the data < ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced multiple oral and poster presentations, ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a bullish call from Wall Street. Canaccord initiated coverage on the stock with a ...

UBS Group upgraded shares of Nanobiotix (NASDAQ:NBTX – Free Report) to a hold rating in a research note issued to investors on Monday morning,Zacks.com reports. Nanobiotix Price Performance ...

While Aditya Jha has made a mark in competitions and exhibitions, his enthusiasm was aptly rewarded when he got accepted to ...